Eine multizentrische, offene Phase-II-Studie mit intratumoralem tavokinogenen Telseplasmid (Tavo, pIL-12) plus Elektroporation in Kombination mit intravenösem Pembrolizumab bei Patienten mit Melanom im Stadium III/IV und Progress während der Behandlung mit Pembrolizumab oder Nivolumab.

Biological: tavokinogene telseplasmid;Biological: Pembrolizumab;Device: ImmunoPulse

Inclusion Criteria:

In order to be eligible for participation in this study, the subject must meet all of the
following:

All Cohorts:

1. Pathologically documented unresectable melanoma, American Joint Committee on Cancer
(AJCC) version 8, Stage III or IV. Subjects must have histological or cytological
confirmed diagnosis of unresectable melanoma with progressive locally advanced or
metastatic disease.

2. Subjects must be refractory to anti-PD-1 monoclonal antibodies (mAb) (pembrolizumab or
nivolumab either as monotherapy or in combination with other approved checkpoint
inhibitors or targeted therapies according to their approved label) and subjects must
meet all of the following criteria:

1. Received treatment of FDA-approved anti-PD1 mAb (dosed per label of the country
providing the clinical site) for at least 12 weeks (eg, 4 administrations of q3w
200 mg pembrolizumab or 2 administrations of q6w 400 mg pembrolizumab).

2. Progressive disease after anti-PD-1 mAb will be defined according to RECIST v1.1.
The initial evidence of PD is to be confirmed by a second assessment, no less
than 4 weeks from the date of the first documented PD, in the absence of rapid
clinical progression. For cases of rapid clinical progression, patients may be
allowed to enroll without a confirmatory scan after discussion with the sponsor.
(This determination is made by the Investigator; the Sponsor will collect imaging
scans for retrospective analysis. Once PD is confirmed, the initial date of PD
documentation will be considered the date of disease progression).

3. Documented disease progression within 12 weeks of the last dose of anti- PD-1
mAb. Subjects who were re-treated with anti-PD-1 mAb and subjects who were on
maintenance with anti-PD-1 mAb will be allowed to enter the study as long as
there is documented PD within 12 weeks of the last treatment date (with anti-PD-1
mAb).

Note: anti-PD-1 combination therapy is acceptable as the last prior treatment and may
include, anti-PD-1 anti-CTLA4 antibody combination therapy and anti-PD-1 combinations
with investigational or injectable therapy.

Cohort 2:

3. Subjects must have received ipilimumab alone or in combination with nivolumab (or
another agent) within approximately 12 months and must meet the following criteria:

1. Subject received 4 doses of ipilimumab (alone or in combination) or stopped
treatment due to treatment-related adverse event, or investigator determined that
the risks of further exposure outweigh the benefits.

2. Subjects with rapid clinical progression after fewer than 4 doses may be allowed
after discussion with the sponsor.

All Cohorts:

4. Resolution/improvement of anti-PD-1 mAb related adverse events (including immune
related AEs; irAEs) back to Grade 0-1 and =10 mg/day prednisone (or equivalent dose)
for irAEs for at least 2 weeks prior to the first dose of study drug:

1. No history of common toxicity criteria adverse events (CTCAE) Grade 4 irAEs from
anti-PD-1 mAb.

2. No history of CTCAE Grade 3 requiring steroid treatment (>10 mg/day prednisone or
equivalent dose) for >12 weeks or CTCAE Grade 2 pneumonitis regardless of steroid
treatment. No history of (non-infectious) pneumonitis or interstitial lung
disease that required steroids, and no current pneumonitis or interstitial lung
disease.

3. Minimum of 4 weeks (washout period) from the last dose of anti-PD-1 mAb

5. BRAF V600 mutation-positive melanoma could have received standard of care targeted
therapy for advanced or metastatic disease (eg, BRAF/MEK inhibitor, alone or in
combination) prior to enrolling on this study; however they do not need to have
progressed on this treatment.

6. Age = 18 years of age on day of signing informed consent.

7. Has a performance status of 0 or 1 on the ECOG Performance Scale, collected within 7
days of initial treatment.

8. Have measurable disease based on RECIST v1.1, with at least one anatomically distinct
lesion. At least one lesion must meet all the following baseline criteria:

1. Accessible for electroporation;

2. Must be accurately measured in at least one dimension (longest diameter in the
plane of measurement is to be recorded) Note: Tumor lesions situated in a
previously irradiated area are considered measurable if progression has been
demonstrated in such lesions

9. Demonstrate adequate organ function. All screening laboratories should be performed
within 10 days of treatment initiation.

10. Women of childbearing potential must have negative pregnancy test (for serum or urine
pregnancy test, within 72 hours or 24 hours, respectively, prior to receiving the
first study drug administration). If the urine test is positive or cannot be confirmed
as negative, a serum pregnancy test will be required.

11. For women of childbearing potential, must be willing to use an adequate method of
contraception from the first day of study treatment (or 14 days prior to the
initiation of study treatment for oral contraception) and through at least 120 days
following last day of study treatment. Acceptable methods include hormonal
contraception (oral contraceptives

- as long as on stable dose, patch, implant, and injection), intrauterine devices, or
double barrier methods (eg, vaginal diaphragm/ vaginal sponge plus condom, or condom
plus spermicidal jelly), sexual abstinence or a vasectomized partner. Women may be
surgically sterile or at least 1-year post-last menstrual period. Note: Abstinence is
acceptable if this is the usual lifestyle and preferred contraception for the subject.

Note: Spermicide alone is not considered sufficient and will not be accepted

12. Male subjects must be surgically sterile or must agree to use adequate method of
contraception when having sex with women of childbearing potential and refrains from
sperm donation during the study treatment period and through at least 120 days
following the last day of study drug administration.. Note: Abstinence is acceptable
if this is the usual lifestyle and preferred contraception for the subject.

13. Able and willing to provide written informed consent and to follow study instructions.

Exclusion Criteria:

1. Subject has disease that is suitable for local therapy administered with curative
intent.

2.